steer trial semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT Semaglutide Cuts Heart Risk 29%

The doctor might then refer the patient to a specialist, leading to more treatmenteven knee surgery

States must cover this indication

Coordinated care between your GP, gastroenterologist, and weight management service optimises safety and treatment outcomes

Some patients benefit from addressing metabolic health sooner using currently licensed options under clinical supervision

Samples were incubated at 80 C for overnight

For us, this is a brand-new tool in our toolbox to benefit the quality of life in these patients." While GLP-1s are being seen as the hearts newest best friend, on the flip side, obesity is one of its worst enemies